Ad
related to: success rate of targeted therapy
Search results
Results From The WOW.Com Content Network
Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, [1] others being hormonal therapy ...
Current treatments include surgery, chemotherapy, radiation and targeted therapy for those who have a cancer with a biomarker. Doctors have good success in treating early-stage lung cancer, so ...
An anti-TL1A monoclonal antibody called tulisokibart may help people with moderate to severe ulcerative colitis achieve clinical remission, a phase 2 trial has found.
In 1998, an international effort [67] identified seven prognostic factors that accurately predict the success rate of conventional treatment in people with locally extensive or advanced-stage Hodgkin lymphoma. Freedom from progression (FFP) at five years was directly related to the number of factors present in a person.
Peptide receptor radionuclide therapy (PRRT) is a type of radionuclide therapy, using a radiopharmaceutical that targets peptide receptors to deliver localised treatment, typically for neuroendocrine tumours (NETs).
The low toxicity results from reducing the drug or therapy exposure to healthy tissue due to the targeted approach of this drug delivery method. [15] Another aspect noticed during previous studies is the efficiency in drug release rate.
Targeted therapy of lung cancer refers to using agents specifically designed to selectively target molecular pathways responsible for, or that substantially drive, the malignant phenotype of lung cancer cells, and as a consequence of this (relative) selectivity, cause fewer toxic effects on normal cells.
Survival or response rate in this trial was approximately 6 months, and was not significantly better in the TTFields group than in the conventional therapy group. The results suggested that TTFields and standard chemotherapy might be equally beneficial to patients in this setting, but with different side-effect profiles.